- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Galmed Pharmaceuticals Ltd (GLMD)
Galmed Pharmaceuticals Ltd stock price live, this page displays NASDAQ GLMD stock exchange data. View the GLMD premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Galmed Pharmaceuticals Ltd real time stock price chart below.
What Is the Galmed Pharmaceuticals Ltd Stock Price Today?
The Galmed Pharmaceuticals Ltd stock price today is 0.571.
What Is the Stock Symbol for Galmed Pharmaceuticals Ltd?
The stock symbol for Galmed Pharmaceuticals Ltd is "GLMD."
What Stock Exchange Does Galmed Pharmaceuticals Ltd Trade On?
Galmed Pharmaceuticals Ltd is listed and trades on the NASDAQ stock exchange.
Is Galmed Pharmaceuticals Ltd a Good Stock to Buy?
Determining whether Galmed Pharmaceuticals Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GLMD quote. (ISIN: IL0011313900)
What Is the Galmed Pharmaceuticals Ltd Stock Price Today?
The Galmed Pharmaceuticals Ltd stock price today is 0.571.
What Is the Stock Symbol for Galmed Pharmaceuticals Ltd?
The stock symbol for Galmed Pharmaceuticals Ltd is "GLMD."
What Stock Exchange Does Galmed Pharmaceuticals Ltd Trade On?
Galmed Pharmaceuticals Ltd is listed and trades on the NASDAQ stock exchange.
Is Galmed Pharmaceuticals Ltd a Good Stock to Buy?
Determining whether Galmed Pharmaceuticals Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GLMD quote. (ISIN: IL0011313900)
0.571
-0.003(-0.45%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.550
0.582
52 wk Range
0.411
2.340
GLMD is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.5500.582
52 wk Range
0.4112.340
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
GLMD Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Neutral
Price Target
0.000
Downside
-100.00%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Form 6K Galmed Pharmaceuticals Ltd For: 22 June
- Investing.com
- Form 6K Galmed Pharmaceuticals Ltd For: 2 June
- Investing.com
- Form 6K Galmed Pharmaceuticals Ltd For: 22 June
- Investing.com
- Form 6K Galmed Pharmaceuticals Ltd For: 8 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell
Analyst Ratings
0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 0.000
Earnings
Latest Release
May 20, 2026
EPS / Forecast
-0.38 / --
Revenue / Forecast
-- / --
Compare GLMD to Peers and Sector
Metrics to compare | GLMD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGLMDPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.4x | −1.5x | −0.4x | |
PEG Ratio | −0.01 | −0.02 | 0.00 | |
Price/Book | 0.2x | 1.1x | 2.6x | |
Price / LTM Sales | - | 16.3x | 3.0x | |
Upside (Analyst Target) | - | 445.5% | 57.0% | |
Fair Value Upside | Unlock | 5.2% | 9.1% | Unlock |
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Galmed Pharma (GLMD) Stock Price Today?
The Galmed Pharma stock price today is 0.571 USD.
What Stock Exchange Does Galmed Pharma Trade On?
Galmed Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Galmed Pharma?
The stock symbol for Galmed Pharma is "GLMD."
What Is the Galmed Pharma Market Cap?
As of today, Galmed Pharma market cap is 3.780M USD.
What Is Galmed Pharma's Earnings Per Share (TTM)?
The Galmed Pharma EPS (TTM) is -2.391.
When Is the Next Galmed Pharma Earnings Date?
Galmed Pharma will release its next earnings report on Jul 30, 2026.
From a Technical Analysis Perspective, Is GLMD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Galmed Pharma Stock Split?
Galmed Pharma has split 2 times.
How Many Employees Does Galmed Pharma Have?
Galmed Pharma has 5 employees.
What is the current trading status of Galmed Pharma (GLMD)?
As of Jun 29, 2026, Galmed Pharma (GLMD) is trading at a price of 0.571 USD, with a previous close of 0.574 USD. The stock has fluctuated within a day range of 0.550 USD to 0.582 USD, while its 52-week range spans from 0.411 USD to 2.340 USD.
What Is the GLMD Premarket Price?
GLMD's last pre-market stock price is 0.546 USD. The pre-market share volume is 150.000, and the stock has decreased by -0.028, or -4.880%.
What Is the GLMD After Hours Price?
GLMD's last after hours stock price is 0.545 USD, the stock has decreased by -0.028, or -4.920%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.